Skip to main content
Erschienen in: Reactions Weekly 1/2020

01.02.2020 | Case report

Immunosuppressants/immunotherapies

Epstein-Barr virus-associated post-transplant lymphoproliferative disorder and sensory polyneuropathy: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Fußnoten
1
In R-CHOP regimen, specific corticosteroid component was not mentioned.
 
Literatur
Zurück zum Zitat Mika T, et al. Refractory Epstein-Barr Virus (EBV)-Related Post-transplant Lymphoproliferative Disease: Cure by Combined Brentuximab Vedotin and Allogeneic EBV-Specific T-Lymphocytes. Frontiers in Medicine 6: Dec 2019. Available from: URL: http://doi.org/10.3389/fmed.2019.00295 Mika T, et al. Refractory Epstein-Barr Virus (EBV)-Related Post-transplant Lymphoproliferative Disease: Cure by Combined Brentuximab Vedotin and Allogeneic EBV-Specific T-Lymphocytes. Frontiers in Medicine 6: Dec 2019. Available from: URL: http://​doi.​org/​10.​3389/​fmed.​2019.​00295
Metadaten
Titel
Immunosuppressants/immunotherapies
Epstein-Barr virus-associated post-transplant lymphoproliferative disorder and sensory polyneuropathy: case report
Publikationsdatum
01.02.2020
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2020
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-020-74984-0

Weitere Artikel der Ausgabe 1/2020

Reactions Weekly 1/2020 Zur Ausgabe

Case report

Crizotinib

Case report

Midazolam

Case report

Amphotericin B